<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00174681</url>
  </required_header>
  <id_info>
    <org_study_id>HOE901_4042</org_study_id>
    <nct_id>NCT00174681</nct_id>
  </id_info>
  <brief_title>Tulip Study: Testing the Usefulness of Lantus When Initiated Prematurely In Patients With Type 2 Diabetes</brief_title>
  <official_title>Testing the Usefulness of Lantus When Initiated Prematurely In Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Primary objective:&#xD;
&#xD;
      The primary objective of this trial is:&#xD;
&#xD;
        -  To evaluate the efficacy of initiating Lantus in combination with oral antidiabetics&#xD;
           drugs compared to oral antidiabetic treatment optimised by enhancing hygienic and&#xD;
           dietary measures in type 2 diabetics whose blood glucose control is acceptable but not&#xD;
           optimal on maximum oral treatment, based on the number of patients achieving a HbA1c&#xD;
           value &lt; 7% at the end of treatment.&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
      The secondary objectives of this trial are to compare between the two treatment groups:&#xD;
&#xD;
        -  The variation in HbA1c between baseline and end of trial.&#xD;
&#xD;
        -  The frequency of episodes of symptomatic hypoglycaemia (diurnal and nocturnal), severe&#xD;
           hypoglycaemia (diurnal and nocturnal) and asymptomatic hypoglycaemia.&#xD;
&#xD;
        -  Mean blood glucose levels at different times of the day.&#xD;
&#xD;
        -  The variation in weight and lipid in each group between baseline and end of trial.&#xD;
&#xD;
        -  The incidence of adverse events.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2003</start_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects achieving HbA1c &lt; 7% at the end of the study.</measure>
  </primary_outcome>
  <enrollment>390</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Glargine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :&#xD;
&#xD;
        Subjects fulfilling all of the following criteria will be eligible for inclusion in the&#xD;
        trial:&#xD;
&#xD;
          -  Type 2 diabetes&#xD;
&#xD;
          -  24 ≤ BMI ≤ 35 kg/m2&#xD;
&#xD;
          -  7 % ≤ HbA1c ≤ 8 %&#xD;
&#xD;
          -  Treated with OAD for at least 2 years&#xD;
&#xD;
          -  Treated with at least two oral antidiabetics including one sulphonylurea at the&#xD;
             maximum tolerated dosages and metformin at the maximum tolerated dosages&#xD;
&#xD;
          -  Not treated with a glinide or thiazolidinedione.&#xD;
&#xD;
          -  Capable of performing blood glucose self-monitoring and a self-injection of insulin.&#xD;
&#xD;
          -  Funduscopy within the previous year at the time of inclusion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patient with any of the following criteria will not be included in the trial:&#xD;
&#xD;
          -  Type 1 diabetics&#xD;
&#xD;
          -  Insulin-treated type 2 diabetics or having previously received long-term insulin, or&#xD;
             treated with a thiazolidinedione or glinide&#xD;
&#xD;
          -  Fasting blood glucose &lt; 1.20 g/l.&#xD;
&#xD;
          -  Pregnancy (non-menopausal women must have a pregnancy test before the inclusion visit&#xD;
             and effective contraception).&#xD;
&#xD;
          -  Lactation.&#xD;
&#xD;
          -  History of hypersensitivity to the investigational product or to drugs with similar&#xD;
             chemical structures.&#xD;
&#xD;
          -  Systemic treatment with corticosteroids irrespective of the dose and irrespective of&#xD;
             the previous or anticipated duration of treatment.&#xD;
&#xD;
          -  Treatment with another product under development in the 2 months preceding the date of&#xD;
             inclusion in the study.&#xD;
&#xD;
          -  Subject likely to receive treatments prohibited in the protocol during the trial.&#xD;
&#xD;
          -  Cardiovascular, hepatic, neurological, endocrine or any other disease making it&#xD;
             difficult to carry out the protocol or interpret the results.&#xD;
&#xD;
          -  Proliferative or rapidly progressive or unstable retinopathy for at least 6 months&#xD;
             after treatment by surgery or laser, or requiring surgery or laser in the 3 months&#xD;
             following inclusion in the study.&#xD;
&#xD;
          -  Hepatic impairment:ALT and/or AST more than three times the upper limit of normal at&#xD;
             the initial assessment.&#xD;
&#xD;
          -  Renal insufficiency:Serum creatinine &gt;177 µmol/l (&gt;20 mg/l) or creatinine clearance&#xD;
             &lt;60 ml/min.&#xD;
&#xD;
          -  Previous or current history of alcohol or drug abuse.&#xD;
&#xD;
          -  Mental state rendering the subject incapable of understanding the nature, objectives&#xD;
             and possible consequences of the trial.&#xD;
&#xD;
          -  Inability to undertake blood glucose self-monitoring and the injection of insulin&#xD;
             alone.&#xD;
&#xD;
          -  Subject unable to accept the restrictions of the protocol (uncooperative, unable to&#xD;
             attend the follow-up visits and probably incapable of completing the trial).&#xD;
&#xD;
          -  Subjects deprived of freedom by an administrative or judicial decision.&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valérie Pilorget, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Ljubljana</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Croatia</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovenia</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>January 10, 2011</last_update_submitted>
  <last_update_submitted_qc>January 10, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2011</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

